izpis_h1_title_alt

Treatment of benign prostatic hyperplasia by natural drugs
ID Csikós, Eszter (Avtor), ID Sollner Dolenc, Marija (Avtor), ID Kenda, Maša (Avtor), ID Kočevar Glavač, Nina (Avtor), ID Farkas, Ágnes (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (561,97 KB)
MD5: 15770863F1F4C399C9B5072BAAACDB5F
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1420-3049/26/23/7141 Povezava se odpre v novem oknu

Izvleček
Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the abovementioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

Jezik:Angleški jezik
Ključne besede:benign prostatic hyperplasia, medicinal plants, phytotherapy, saw palmetto, preclinical studies, clinical efficacy, safety issues
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:32 str.
Številčenje:Vol. 26, iss. 23, art. 7141
PID:20.500.12556/RUL-136713 Povezava se odpre v novem oknu
UDK:616.65-007.61
ISSN pri članku:1420-3049
DOI:10.3390/molecules26237141 Povezava se odpre v novem oknu
COBISS.SI-ID:86644739 Povezava se odpre v novem oknu
Datum objave v RUL:17.05.2022
Število ogledov:586
Število prenosov:117
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Molecules
Skrajšan naslov:Molecules
Založnik:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:01.12.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:predklinične študije, klinična učinkovitost, varnostne težave

Projekti

Financer:EC - European Commission
Program financ.:Erasmus+, Key Action 2: Strategic Partnerships
Številka projekta:2020-1-CZ01-KA203-078218
Naslov:Open Access Educational Materials on Naturally Occurring Molecules

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj